Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 27, 2025 04:31 ET | Source: Research and Markets

Base Editing Market Research and Forecasts 2024-2034: Expansion of Oncology Applications, and a Rise in Partnerships and Collaborations Fuel Opportunities

Dublin, Jan. 27, 2025 (GLOBE NEWSWIRE) -- The "Base Editing Market by Products & Services, by Type, by Application, by End-User, and By Region" report has been added to ResearchAndMarkets.com's...
December 05, 2024 01:39 ET | Source: Base Therapeutics

World’s First Zero-Off-Target Base-edited NK Cell Therapy Receives IND Approval in Both China and the U.S.

The world’s first zero-off-target base-edited NK cell product has received IND approvals from both the U.S. FDA and China’s NMPA.
February 13, 2024 09:49 ET | Source: Research and Markets

Base Editing Market Research Report 2023 - Global Forecasts to 2028: Innovative Molecules Engineered to Tackle Rare Genetic Disorders at the Fore-font of Developments

Dublin, Feb. 13, 2024 (GLOBE NEWSWIRE) -- The "Global Base Editing Market by Product (Platform, Reagents & Kits, Plasmids), Service (gRNA Design, Cell Line Engineering), Type, Targeted Base...
November 10, 2021 07:30 ET | Source: Exavir Therapeutics

Exavir Therapeutics announces preclinical data demonstrating complete elimination of HIV from human cells with LNP-delivered Tat-targeted CRISPR-Cas9

Early candidate from XVIR-TAT series demonstrated genetic elimination of HIV and robust anti-retroviral activity with CRISPR-Cas9 based excision Exavir lipid nanoparticles (LNPs) with mRNA...
November 20, 2020 16:01 ET | Source: Beam Therapeutics

The Boston Globe Names Beam Therapeutics a Top Place to Work for 2020

CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today has been named...
March 16, 2020 07:00 ET | Source: Beam Therapeutics

Beam Therapeutics Announces Key R&D Appointments

CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced key...